Avadel Pharmaceuticals (AVDL) Income from Continuing Operations: 2009-2021
Historic Income from Continuing Operations for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' Income from Continuing Operations fell 894.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 514.63%. This contributed to the annual value of -$85.5 million for FY2021, which is 1253.58% down from last year.
- As of Q4 2021, Avadel Pharmaceuticals' Income from Continuing Operations stood at -$23.1 million, which was up 9.85% from -$25.7 million recorded in Q3 2021.
- In the past 5 years, Avadel Pharmaceuticals' Income from Continuing Operations registered a high of $45.7 million during Q2 2020, and its lowest value of -$63.9 million during Q4 2018.
- In the last 3 years, Avadel Pharmaceuticals' Income from Continuing Operations had a median value of -$12.4 million in 2019 and averaged -$11.9 million.
- In the last 5 years, Avadel Pharmaceuticals' Income from Continuing Operations spiked by 630.81% in 2020 and then plummeted by 894.24% in 2021.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Income from Continuing Operations stood at -$8.2 million in 2017, then tumbled by 674.52% to -$63.9 million in 2018, then climbed by 28.68% to -$45.5 million in 2019, then skyrocketed by 94.89% to -$2.3 million in 2020, then tumbled by 894.24% to -$23.1 million in 2021.
- Its Income from Continuing Operations was -$23.1 million in Q4 2021, compared to -$25.7 million in Q3 2021 and -$23.3 million in Q2 2021.